Sterling Capital Management’s Genmab GMAB Stock Holding History

Sterling Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$497K	Sell	18,110 -1,752	-9%	-$46.6K	0.01%	810
2026 Q1	$533K	Sell	19,862 -1,858	-9%	-$55.7K	0.01%	748
2025 Q4	$669K	Buy	21,720 +8,140	+60%	+$254K	0.01%	802
2025 Q3	$416K	Sell	13,580 -5,334	-28%	-$130K	0.01%	1032
2025 Q2	$391K	Sell	18,914 -1,024	-5%	-$21K	0.01%	1038
2025 Q1	$390K	Buy	19,938 +1,286	+7%	+$27K	0.01%	965
2024 Q4	$389K	Sell	18,652 -5,756	-24%	-$126K	0.01%	1061
2024 Q3	$595K	Buy	+24,408	New	+$653K	0.01%	770

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's GMAB Position: Q2 2026 in Review

Sterling Capital Management reduced its Genmab (GMAB) stake by 8.8% in Q2 2026, selling an estimated $46.6K and leaving 18,110 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #810.

Sterling Capital Management first reported a position in GMAB in Q3 2024 and has held it in 8 quarters since. The position peaked at $669K in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Sterling Capital Management held 18,110 shares of Genmab worth $497K as of Q2 2026.
Sterling Capital Management sold 1,752 Genmab shares in Q2 2026, an estimated $46.6K.
Genmab made up 0.01% of Sterling Capital Management's portfolio in Q2 2026, its #810 holding.
Sterling Capital Management first reported a position in Genmab in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Genmab position peaked at $669K in Q4 2025.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.